A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study 由 Mead, AJ, Butt, NM, Nagi, W, Whiteway, A, Kirkpatrick, S, Rinaldi, C, Roughley, C, Ackroyd, S, Ewing, J, Neelakantan, P, Garg, M, Tucker, D, Murphy, J, Patel, H, Bains, R, Chiu, G, Hickey, J, Harrison, C, Somervaille, TCP

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline 由 McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF

Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis 由 Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S